Vanguard Group
BHVN icon

Vanguard Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Vanguard Group’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,439,571
Closed -$218M – 4644
2022
Q3 		$218M Buy
1,439,571
+7,113
+0.5% +$1.05M 0.01% 1333
2022
Q2 		$209M Buy
1,432,458
+10,732
+0.8% +$1.37M 0.01% 1399
2022
Q1 		$169M Buy
1,421,726
+52,635
+4% +$6.56M ﹤0.01% 1649
2021
Q4 		$189M Sell
1,369,091
-8,890
-0.6% -$1.13M ﹤0.01% 1648
2021
Q3 		$191M Buy
1,377,981
+56,711
+4% +$7.08M ﹤0.01% 1638
2021
Q2 		$128M Buy
1,321,270
+48,374
+4% +$3.93M ﹤0.01% 1862
2021
Q1 		$87M Buy
1,272,896
+124,655
+11% +$10.1M ﹤0.01% 2025
2020
Q4 		$98.4M Buy
1,148,241
+97,739
+9% +$8.28M ﹤0.01% 1842
2020
Q3 		$68.3M Sell
1,050,502
-454,285
-30% -$29.8M ﹤0.01% 1861
2020
Q2 		$110M Buy
1,504,787
+110,271
+8% +$5.87M ﹤0.01% 1624
2020
Q1 		$47.5M Buy
1,394,516
+383,632
+38% +$17.5M ﹤0.01% 1888
2019
Q4 		$55M Buy
1,010,884
+118,639
+13% +$5.87M ﹤0.01% 2062
2019
Q3 		$37.2M Sell
892,245
-262,012
-23% -$11.1M ﹤0.01% 2207
2019
Q2 		$50.5M Buy
1,154,257
+294,098
+34% +$16.6M ﹤0.01% 2097
2019
Q1 		$44.3M Buy
860,159
+191,923
+29% +$8.29M ﹤0.01% 2151
2018
Q4 		$24.7M Buy
668,236
+131,725
+25% +$4.75M ﹤0.01% 2357
2018
Q3 		$20.1M Buy
536,511
+20,785
+4% +$765K ﹤0.01% 2575
2018
Q2 		$20.4M Buy
515,726
+228,776
+80% +$7.26M ﹤0.01% 2556
2018
Q1 		$7.39M Buy
286,950
+100,487
+54% +$3M ﹤0.01% 2972
2017
Q4 		$5.03M Buy
186,463
+50,615
+37% +$1.39M ﹤0.01% 3136
2017
Q3 		$5.08M Buy
135,848
+7,746
+6% +$235K ﹤0.01% 3113
2017
Q2 		$3.2M Buy
+128,102
New +$2.95M ﹤0.01% 3243

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Vanguard Group's BHVN Position: Q4 2022 in Review

Vanguard Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 1,439,571 shares — an estimated $218M sold.

Vanguard Group first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $218M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Vanguard Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Vanguard Group sold 1,439,571 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $218M.
  • Vanguard Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Vanguard Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $218M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Vanguard Group's 13F filing for Q4 2022, filed 10 Feb 2023.